Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (17)

Advertisement

Free access | 10.1172/JCI108814

Phytohemagglutinin Response in Systemic Lupus Erythematosus: RECONSTITUTION EXPERIMENTS USING HIGHLY PURIFIED LYMPHOCYTE SUBPOPULATIONS AND MONOCYTES

Peter D. Utsinger and William J. Yount

Division of Immunology and Rheumatology, Department of Medicine and Bacteriology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

Find articles by Utsinger, P. in: PubMed | Google Scholar

Division of Immunology and Rheumatology, Department of Medicine and Bacteriology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

Find articles by Yount, W. in: PubMed | Google Scholar

Published September 1, 1977 - More info

Published in Volume 60, Issue 3 on September 1, 1977
J Clin Invest. 1977;60(3):626–638. https://doi.org/10.1172/JCI108814.
© 1977 The American Society for Clinical Investigation
Published September 1, 1977 - Version history
View PDF
Abstract

The phytohemagglutinin (PHA) response of lymphocytes from untreated patients with systemic lupus erythematosus (SLE) was studied using highly purified subpopulations of cells involved in the transformation response: T lymphocytes, B lymphocytes, and monocytes. Cell transformation was quantitated using both tritiated thymidine ([3H]-TdR) incorporation into DNA and cytofluorographic determination of cellular DNA content. Dose-response curves using six concentrations of PHA and five concentrations of cells over 0-5 days revealed a decrease in [3H]TdR by stimulated lymphocytes from some SLE patients. This decrease in [3H]TdR was paralleled by a decreased percentage of cells in S, G2, and M phases of the cell cycle. However, abnormal response occurred entirely in those SLE patients who were hypocomplementemic. The etiology of the impaired response was further examined. Lymphocyte receptors for concanavalin A were studied using cytofluorography of lymphocytes stained with fluorescein-conjugated concanavalin A. The frequency distribution of concanavalin A receptors was similar in the normocomplementemic and hypocomplementemic lupus patients and in normals. The latex phagocytic activity of lupus macrophages was similar to normals when allogeneic normal plasma was used in the culture medium. Phagocytic activity became abnormal in the presence of SLE plasma. However, there was no difference in the [3H]TdR response or the percentage of cells in S, G2, and M phases when T lymphocytes from the hypocomplementemic patients were stimulated on either autologous or normal allogeneic monocyte monolayers. Likewise, normal lymphocytes incorporated similar amounts of [3H]TdR and had similar percentages of cells in S, G2, and M phases whether their T lymphocytes were stimulated on autologous or SLE monocyte monolayers. Highly purified subpopulations of B and T lymphocytes were obtained by density sedimentation or Fenwal Leuko-Pak passage of lymphocyte populations. The response to PHA by lymphocytes from the hypocomplementemic lupus patients could be seen to involve at least two abnormalities. One, in reference to normal lymphocytes, SLE T lymphocytes plus monocytes had an impaired response; two, SLE B lymphocytes plus SLE T lymphocytes plus SLE monocytes had an impaired response. Two patients in the hypocomplementemic group were treated with steroids. 5 days after steroid treatment was initiated, the percentage of cells in S, G2, and M phases and the [3H]TdR response of PHA-stimulated lymphocytes returned to normal. The normalization of the [3H]TdR response was explained both by a return of purified T cells plus monocytes, purified B cells plus monocytes, and whole lymphocyte populations to normal responsiveness. These studies suggest that a steroid-correctable defect exists in T and B lymphocytes in SLE.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 626
page 626
icon of scanned page 627
page 627
icon of scanned page 628
page 628
icon of scanned page 629
page 629
icon of scanned page 630
page 630
icon of scanned page 631
page 631
icon of scanned page 632
page 632
icon of scanned page 633
page 633
icon of scanned page 634
page 634
icon of scanned page 635
page 635
icon of scanned page 636
page 636
icon of scanned page 637
page 637
icon of scanned page 638
page 638
Version history
  • Version 1 (September 1, 1977): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (17)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts